Taiwan Association for the Study of the Liver-Tai-wan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction-associated fatty liver disease and cardiovascular diseases

Pin Nan Cheng, Wen Jone Chen, Charles Jia Yin Hou, Chih Lin Lin, Ming Ling Chang, Chia Chi Wang, Wei Ting Chang, Chao Yung Wang, Chun Yen Lin, Chung Lieh Hung, Cheng Yuan Peng, Ming Lung Yu, Ting Hsing Chao, Jee Fu Huang, Yi Hsiang Huang, Chi Yi Chen, Chern En Chiang, Han Chieh Lin, Yi Heng Li, Tsung Hsien LinJia Horng Kao, Tzung Dau Wang, Ping Yen Liu, Yen Wen Wu, Chun Jen Liu

研究成果: Review article同行評審

1 引文 斯高帕斯(Scopus)

摘要

Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on images, histological findings, or serum marker levels as well as the presence of at least one of the three metabolic features: overweight/obesity, type 2 diabetes mellitus, and metabolic risk factors. MAFLD is not only a liver disease but also a factor contributing to or related to cardiovascular diseases (CVD), which is the major etiology responsible for morbidity and mortality in patients with MAFLD. Hence, understanding the association between MAFLD and CVD, surveillance and risk stratification of MAFLD in patients with CVD, and assessment of the current status of MAFLD management are urgent requirements for both hepatologists and cardiologists. This Taiwan position statement reviews the literature and provides suggestions regarding the epidemiology, etiology, risk factors, risk stratification, nonpharmacological interventions, and potential drug treatments of MAFLD, focusing on its association with CVD. (Clin Mol Hepatol 2024;30:16-36).

原文English
頁(從 - 到)16-36
頁數21
期刊Clinical and molecular hepatology
30
發行號1
DOIs
出版狀態Published - 2024 1月

All Science Journal Classification (ASJC) codes

  • 肝病
  • 分子生物學

指紋

深入研究「Taiwan Association for the Study of the Liver-Tai-wan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction-associated fatty liver disease and cardiovascular diseases」主題。共同形成了獨特的指紋。

引用此